Preparation method and application of traditional Chinese medicine monomer hydrogel for treating type I herpes simplex
By functionalizing baicalin and chitosan and combining with polyvinyl alcohol solution, the problem of acyclovir being ineffective against HSV-1 resistant strains and easy oxidation of baicalin is solved, and the I of the Effective treatment of herpes simplex provides a new strategy for drug-resistant skin herpes.
Patent Information
- Application Number
- CN202411005777.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-15
AI Technical Summary
The existing acyclovir treatment is ineffective against drug-resistant strains of type I herpes simplex virus (HSV-1), and baicalin is prone to oxidation, resulting in low bioavailability, making it difficult to effectively treat drug-resistant skin herpes.
The traditional Chinese medicine monomer hydrogel was prepared by functional modification of baicalin and chitosan through p-formylbenzene boric acid and 3,4-dihydroxybenzaldehyde combined with polyvinyl alcohol solution to form water absorption, water retention, low pH and high ROS response Chinese herbal monomer hydrogel is used to treat type I herpes simplex.
This Chinese medicine monomer hydrogel has good adhesion, antioxidant and anti-inflammatory capabilities, can effectively inhibit the infection of HSV-1 and acyclovir resistant strains, improve the bioavailability of baicalin, and provide slow-controlled release and anti-tensioning properties, promote skin healing, and are suitable for the treatment of skin herpes induced by drug-resistant HSV-1.
Smart Images

Figure CN118948744A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to biomaterials, and in particular to a preparation method and application of a traditional Chinese medicine monomer hydrogel for treating herpes simplex type I. Background Art
[0002] Skin herpes is mostly caused by infection with herpes simplex virus type 1 (HSV-1). After HSV-1 contacts the host, it first lyses and infects the epithelial cells of the peripheral skin tissue, causing clustered blisters on the skin and mucous membranes, accompanied by burning, itching or pain symptoms, which are unbearable for patients. At present, the main treatment strategy for skin herpes is to use acyclovir gel / ointment for treatment, which effectively inhibits the DNA synthesis of HSV-1 and relieves symptoms. Unfortunately, there have been reports of acyclovir-resistant strains in clinical practice, and there is an urgent need to find new drugs against HSV-1 resistant strains to meet the challenge.
[0003] Baicalin belongs to the flavonoids and has non-specific activity against viral infection. Previous studies have shown that baicalin can effectively inhibit the infection of HSV-1 and acyclovir-resistant strains in vivo and in vitro, and reduce the viral load in tissues and cells. Its mechanism of action is related to the direct inactivation of viral particles by baicalin and the activation of the NFκB pathway. However, due to the easy oxidation of baicalin and its short half-life, its bioavailability is low, which is the key to restricting the pharmacological activity and clinical use of baicalin.
[0004] As a biomaterial with a three-dimensional network structure, hydrogel has good drug loading performance. It can increase the retention of drugs in the lesions and play a role of sustained release, reduce the number of medications and thus reduce adverse drug reactions. Summary of the invention
[0005] The present invention provides a method for preparing a Chinese medicine monomer hydrogel for treating type I herpes simplex. The present invention uses baicalin and chitosan as main raw materials, and chitosan is functionalized and modified with p-formylphenylboronic acid and 3,4-dihydroxybenzaldehyde, and then prepared into a Chinese medicine monomer hydrogel with baicalin. The Chinese medicine monomer hydrogel has the characteristics of water absorption and water retention, and also has the effects of low pH and high ROS responsiveness, etc., and can achieve rapid healing of skin herpes, providing a new strategy for the future treatment of skin herpes induced by drug-resistant herpes simplex virus.
[0006] Specifically, a method for preparing a traditional Chinese medicine monomer hydrogel for treating herpes simplex type I comprises: reacting chitosan with p-formylphenylboronic acid and 3,4-dihydroxybenzaldehyde to undergo a Schiff base reaction, and then reducing and aminating the chitosan under the action of sodium cyanoborohydride to obtain chitosan functionalized with phenylboronic acid and catechol, and then mixing the chitosan with a polyvinyl alcohol solution containing baicalein to obtain the traditional Chinese medicine monomer hydrogel.
[0007] The chitosan has a medium viscosity, that is, a viscosity of 200-400 mPa·s.
[0008] The structure of baicalin is
[0009] The structure of chitosan functionalized with phenylboronic acid and catechol obtained by the present invention is:
[0010] Among them, m:n=1:1~10:1.
[0011] The specific operation steps of the present invention include:
[0012] (1) dispersing baicalein in a polyvinyl alcohol solution to obtain a baicalein-polyvinyl alcohol mixed solution;
[0013] (2) dissolving chitosan under acidic conditions, adding p-formylphenylboric acid, 3,4-dihydroxybenzaldehyde and sodium cyanoborohydride to react, dialysis and freeze-drying after the reaction, and re-dissolving to obtain a chitosan mixed solution;
[0014] (3) Mix the baicalein polyvinyl alcohol solution and chitosan solution and vortex them in a mixer to prepare a mixed solution.
[0015] In step (1), in the baicalein-polyvinyl alcohol mixed solution, the concentration of baicalein is 10.0 mM to 40.0 mM, and the concentration of polyvinyl alcohol is 1.0 wt% to 3.0 wt%.
[0016] The acidic condition in step (2) is glacial acetic acid with a concentration of 0.5wt% to 2.0wt%.
[0017] In step (2), the p-formylphenylboronic acid and 3,4-dihydroxybenzaldehyde are dissolved in N,N-dimethylformamide respectively and then added.
[0018] In step (2), after adding p-formylphenylboronic acid and reacting for 10 to 14 hours, 3,4-dihydroxybenzaldehyde is added and reacted for 10 to 14 hours, and sodium cyanoborohydride is added.
[0019] In step (2), the dialysis condition is 14000 molecular weight dialysis bag, dialysis for 3 days, and water is changed three times a day.
[0020] In step (2), the freeze-drying time is 48 h to 72 h.
[0021] In the reconstituted chitosan solution in step (2), the chitosan concentration is 1.0 wt% to 2.0 wt%.
[0022] In step (3), the baicalein polyvinyl alcohol solution and the chitosan mixed solution are mixed in a volume ratio of 1:0.5 to 1:1.3.
[0023] In step (3), the vortex time is 0.5 min to 3.0 min.
[0024] The second object of the present invention is to provide a traditional Chinese medicine monomer hydrogel for treating herpes simplex type I obtained by the above preparation method.
[0025] The third object of the present invention is to use the traditional Chinese medicine monomer hydrogel as a drug for treating herpes simplex type I.
[0026] Compared with the prior art, the present invention has the following advantages:
[0027] 1. The Chinese medicine monomer hydrogel provided by the present invention has good adhesion, antioxidant and anti-inflammatory capabilities. Among them, baicalin can effectively inhibit the infection of HSV-1F strains and acyclovir-resistant strains commonly seen in clinical practice. The present invention has no negative effect on the skin barrier function, can effectively absorb wound exudates, and inactivates virus particles by slowly releasing baicalin, providing a relatively sterile, virus-free and hypoxic environment for the wound surface, which helps the healing of skin herpes.
[0028] 2. The preparation method of the Chinese medicine monomer hydrogel provided by the present invention increases the drug loading in the hydrogel by dispersing baicalein in a polyvinyl alcohol solution on the one hand, and reduces the hydrophobicity of baicalein by utilizing the solubilizing effect of polyvinyl alcohol on the other hand, thereby improving the bioavailability of the drug. The Chinese medicine monomer hydrogel can responsively control the release of drugs under the conditions of low pH and high ROS in the characteristic microenvironment of herpes, has stretchability and good adhesion properties, can meet the clinical needs of skin herpes and special microenvironments, and chitosan has the characteristics of natural antibacterial and excellent biocompatibility, etc., which provides a new strategy for the treatment of skin herpes.
[0029] 3. The preparation method of the Chinese medicine monomer hydrogel provided by the present invention, the raw materials baicalin and polyvinyl alcohol, can make full use of the characteristics of polyvinyl alcohol dispersing baicalin, effectively reduce the in vitro oxidation of baicalin and enhance the transdermal absorption of baicalin, penetrate the skin barrier, reach the dermis and subcutaneous tissue, kill viruses, and relieve symptoms. In addition, the addition of polyvinyl alcohol can also improve the mechanical properties of the hydrogel and give the hydrogel excellent tensile resistance.
[0030] 4. The preparation method of the traditional Chinese medicine monomer hydrogel provided by the present invention, the raw material p-formylphenylboronic acid has low pH and high ROS environmental response, and the functional hydrogel is obtained by using it as the raw material to achieve sustained-release performance.
[0031] 5. The preparation method of the traditional Chinese medicine monomer hydrogel provided by the present invention, the raw material 3,4-dihydroxybenzaldehyde provides excellent adhesion properties for the hydrogel, which is helpful for use in dressings for the treatment of skin herpes.
[0032] 6. The preparation method of the traditional Chinese medicine monomer hydrogel provided by the present invention has reliable principle and is suitable for wide application. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 This is a Fourier transform infrared spectrum of chitosan co-grafted with phenylboronic acid and catechol prepared in Example 1;
[0034] Figure 2 This is the hydrogen nuclear magnetic resonance spectrum of chitosan co-grafted with phenylboronic acid and catechol prepared in Example 1;
[0035] Wherein, A is a schematic diagram of the structure of the prepared phenylboronic acid catechol modified chitosan, and B is a hydrogen nuclear magnetic resonance spectrum of the compound;
[0036] Figure 3 The X-ray diffraction pattern (XRD) of chitosan co-grafted with phenylboronic acid and catechol prepared in Example 1;
[0037] Figure 4 Schematic diagram of the bending and stretching of the traditional Chinese medicine monomer hydrogel prepared in Example 3 at the finger joints and the torsion adhesion on the pig skin;
[0038] Figure 5 This is a scanning electron microscope image (SEM) of the traditional Chinese medicine monomer hydrogel prepared in Example 3;
[0039] Figure 6 The responsive release curve of the traditional Chinese medicine monomer hydrogel prepared in Example 3;
[0040] Figure 7 The results of the efficacy of Examples 2-4 and the comparative example in treating HSV-1 infection at the cellular level are shown;
[0041] A is the viral load of HSV-1F strain infection treated in Hacat and HFF-1 cells by Examples 2, 3, 4 and Comparative Examples 1 and 2; B is the viral load of HSV-1 acyclovir-resistant strain infection treated in Hacat and HFF-1 cells by Examples 2, 3, 4 and Comparative Examples 1 and 2; wherein green is viral protein and blue is cell nucleus;
[0042] Figure 8 The results of the examples and comparative examples on the efficacy of treating HSV-1 infection-induced mouse skin herpes at the animal level;
[0043] AB. Representative pictures of the treatment of skin herpes in mice induced by HSV-1F strain in Examples 2, 3, 4 and Comparative Examples 1 and 3 respectively; CD. Representative pictures of the treatment of skin herpes in mice induced by HSV-1 acyclovir-resistant strain in Examples 2, 3, 4 and Comparative Examples 1 and 3 respectively;
[0044] Fig. 9The H&E staining results of the examples and comparative examples for treating HSV-1 infection-induced mouse skin herpes at the animal level;
[0045] AB. H&E staining pictures of the skin herpes of mice induced by HSV-1F strain treated by Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively; CD. H&E staining pictures of the skin herpes of mice induced by HSV-1 acyclovir-resistant strain treated by Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively;
[0046] Fig.10 The immunohistochemical staining results of the examples and comparative examples for treating HSV-1 infection-induced mouse skin herpes at the animal level;
[0047] AB. Immunohistochemical staining of the skin herpes of mice induced by HSV-1F strain in Examples 2, 3, 4 and Comparative Examples 1 and 3 respectively; CD. Immunohistochemical staining of the skin herpes of mice induced by HSV-1 acyclovir-resistant strain in Examples 2, 3, 4 and Comparative Examples 1 and 3 respectively;
[0048] Fig.11 The results of the examples and comparative examples on reducing the ROS content in tissues when treating HSV-1 infected skin herpes in mice at the animal level;
[0049] AB. are representative pictures of detecting ROS in tissues after treating skin herpes induced by HSV-1F strain in mice in Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively; CD. are representative pictures of detecting ROS in tissues after treating skin herpes induced by HSV-1 acyclovir-resistant strain in mice in Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively;
[0050] Fig.12 The results of the test of viral protein ICP27 content in treating HSV-1 infected mouse skin herpes at the animal level in the examples and comparative examples;
[0051] A. The results of the ICP27 content detection of the viral protein in the treatment of HSV-1F strain-induced mouse skin herpes in Examples 2, 3, 4 and Comparative Examples 1 and 3 respectively; B. The results of the ICP27 content detection of the viral protein in the treatment of HSV-1 acyclovir-resistant strain-induced mouse skin herpes in Examples 2, 3, 4 and Comparative Examples 1 and 3 respectively;
[0052] Fig.13 The results of the test of the expression level of NF-κB pathway proteins in the treatment of skin herpes in mice infected with HSV-1 at the animal level in the examples and comparative examples;
[0053] A. The expression levels of NF-κB pathway proteins in Examples 2, 3, 4 and Comparative Examples 1 and 3 for treating HSV-1F strain-induced mouse skin herpes; B. The expression levels of NF-κB pathway proteins in Examples 2, 3, 4 and Comparative Examples 1 and 3 for treating HSV-1 acyclovir-resistant strain-induced mouse skin herpes. DETAILED DESCRIPTION
[0054] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.
[0055] Example 1
[0056] Chitosan co-grafted with phenylboronic acid and catechol includes the following synthesis steps:
[0057] 1.0000 g of medium viscosity chitosan was dissolved in 100 mL of purified water under 2 mL of glacial acetic acid, and equimolar concentrations of p-formylphenylboric acid, 3,4-dihydroxybenzaldehyde and three times equivalent of sodium cyanoborohydride were added successively. After dialysis for 3 days, the mixture was freeze-dried for 48 hours to obtain chitosan co-grafted with phenylboric acid and catechol.
[0058] Figure 1 The Fourier transform infrared spectrum shows that the 758 cm -1 The peak corresponding to the out-of-plane bending vibration of the trisubstituted CH ring of 3,4-dihydroxybenzaldehyde is 1404 cm -1 The corresponding position is the vibration of the boronic acid group (BO).
[0059] Figure 2 A schematic diagram of the structure of chitosan modified with phenylboronic acid catechol. Figure 2 The hydrogen nuclear magnetic resonance spectrum of B showed that the corresponding proton peaks of chitosan were found in the chitosan modified with phenylboronic acid catechol, and the proton peaks on the benzene ring of 4-formylphenylboronic acid and 3,4-dihydroxybenzaldehyde appeared one by one at a and b of the chitosan modified with phenylboronic acid catechol.
[0060] Figure 3 The XRD curve of chitosan shows that a broad characteristic diffraction peak appears at 20.3° at 2θ, and a flat shoulder-shaped diffraction peak appears at 10.7° at 2θ. This is because chitosan macromolecules have good regularity and are easier to form a crystalline structure. The diffraction peak at 10.7° at 2θ disappears in chitosan modified with phenylboronic acid and chitosan modified with phenylboronic acid catechol, indicating that the lattice structure parameters of chitosan macromolecules change after modification.
[0061] Example 2
[0062] Preparation of blank hydrogel:
[0063] The chitosan grafted with phenylboronic acid and catechol in Example 1 was redissolved in a water bath at 60° C. to prepare a 2 wt % chitosan mixed solution. The 2 wt % polyvinyl alcohol solution and the chitosan mixed solution A were mixed in equal volumes and vortexed in a mixer for two minutes to obtain a blank hydrogel.
[0064] Example 3
[0065] Preparation of Chinese medicine monomer hydrogel:
[0066] 1.00 mg of baicalein was dispersed in a 2 wt% polyvinyl alcohol solution to obtain a baicalein polyvinyl alcohol mixed solution. The chitosan co-grafted with phenylboronic acid and catechol in Example 1 was redissolved in a 60°C water bath to prepare a 2 wt% chitosan mixed solution. The baicalein polyvinyl alcohol solution and the chitosan mixed solution were mixed in equal volumes and vortexed in a mixer for two minutes to obtain a Chinese medicine monomer hydrogel.
[0067] Figure 4 This is a schematic diagram of the bending and stretching of the Chinese medicine monomer hydrogel at the finger joints and the torsion adhesion on the pig skin, showing that the Chinese medicine monomer hydrogel has good ductility and adhesion and its practicality as a dressing.
[0068] Figure 5 In the scanning electron microscope (SEM) image, the three-dimensional network structure of the hydrogel can be clearly observed, which is conducive to the loading of drugs. Figure 6 The responsive release curves showed that the release was different under pH 4.0, pH 6.8 and pH 7.4 conditions, with the fastest release at pH 4.0. 2 O 2 Under these conditions, the release of baicalin reached more than 90% in 24 hours, showing good response performance.
[0069] Example 4
[0070] Preparation of Chinese medicine monomer hydrogel:
[0071] 5.00 mg of baicalein was dispersed in a 2 wt% polyvinyl alcohol solution to obtain a baicalein polyvinyl alcohol mixed solution. The chitosan co-grafted with phenylboronic acid and catechol in Example 1 was redissolved in a 60°C water bath to prepare a 2 wt% chitosan mixed solution. The baicalein polyvinyl alcohol solution and the chitosan mixed solution were mixed in equal volumes and vortexed for two minutes to immediately form a Chinese medicine monomer hydrogel.
[0072] Comparative Example 1
[0073] Baicalein standard, catalog number: 59744D, Adamas Reagent Co., Ltd.
[0074] Comparative Example 2
[0075] Acyclovir standard, product number: S24717-1g, Shanghai Yuanye Biotechnology Co., Ltd.
[0076] Comparative Example 3
[0077] Acyclovir hydrogel, batch number: H20058458, Shandong Fangming Pharmaceutical Group.
[0078] Experimental example
[0079] HaCat and HFF-1 cells were cultured in DMEM containing 10% fetal bovine serum and passaged. Before virus infection, the cells were washed with PBS to remove residual fetal bovine serum components, and the virus solution was diluted with pure culture medium and infected for 2 hours, with slow shaking every 20 minutes. After 2 hours, the virus solution was washed with PBS and the growth was maintained with DMEM containing 2% fetal bovine serum. After 48 hours of culture, the cells were fixed with 4% formaldehyde solution, blocked and perforated, and primary and secondary antibodies were applied before observation under a fluorescence microscope. Figure 7 As shown, after HSV-1 infection, the virus control group and Example 2 group showed large-area fluorescence, Example 3 had a weak anti-HSV-1 effect, Comparative Example 2 could only inhibit the HSV-1EGFP strain, and was ineffective against the Blue strain (the virus strain was resistant to acyclovir), while Comparative Example 1 and Example 4 could effectively inhibit the replication of the HSV-1EGFP strain and the Blue strain.
[0080] After removing the hair on the legs and lips of 4-week-old BALB / c mice, a one-day recovery period was given. On the second day, a scalpel was used to make a wound about 1 cm long on the skin, and the lip tissue was repeatedly punctured vertically 10 times with a 25G needle. Then, the virus dilution was applied to the wounds of each group of mice except the normal group. The virus group mice were coated with normal saline on the wound, the mice in the comparative example 1 group were treated with a 2.5% volume fraction of normal saline solution prepared with a baicalein standard, the mice in the example 2 group were treated with blank hydrogel, the example 3 group and the example 3 group were treated with 0.5% and 2.5% volume fractions of traditional Chinese medicine monomer hydrogel, respectively, and the comparative example 2 group was treated with commercially available acyclovir gel. The drug was changed every 2 days, and the drug was continuously administered for 14 days, and the pathological conditions of the mouse lip tissue and leg skin were recorded daily. On the 7th day after virus infection, three mice in each group were dislocated and killed, and the lesion tissue was separated and collected for pathological detection.
[0081] Hematoxylin-eosin (H&E) staining: After dewaxing and hydration, the sections were immersed in hematoxylin for 2 minutes, washed with running water, and then stained with eosin for 1 minute. After washing with running water, the sections were dehydrated, evaporated, and sealed.
[0082] Immunohistochemical staining: After the sections are dewaxed and hydrated, the tissue antigens are repaired, and then the holes are sealed and punched, and the primary antibody is applied overnight. After washing, the enzyme-coupled secondary antibody is applied for color development. After washing away the excess substrate, hematoxylin staining is performed for 2 minutes, and the sections are washed with running water, dehydrated, evaporated, and sealed.
[0083] Detection of reactive oxygen species (ROS) content in frozen sections: Apply cleaning solution to frozen sections for 5 minutes, add staining solution after washing, and incubate at 37°C in the dark for 30 minutes. After washing away the staining solution, wash the sections 3 times with PBS and seal the sections.
[0084] Western blotting method: The tissue is added to the lysis buffer and homogenized to extract proteins. After denaturation, gel electrophoresis is performed to gradient separate the proteins. After electrophoresis, transfer, blocking, incubation with primary and secondary antibodies, ECL color development is performed.
[0085] like Figure 8 As shown, the lip tissue of mice in the virus control group developed obvious blister lesions on the fourth day, and then these small groups of blisters merged, dried and formed scabs. The infection of the leg skin was more serious, forming extensive blister and erosive rashes. Unlike cytopathology, the comparative example 1 group did not show a good therapeutic effect, which may be related to the fact that baicalin directly applied externally is easily oxidized and has poor transdermal absorption. Example 2 can protect baicalin from oxidation, and the transdermal absorbent PVA in the material promotes baicalin to penetrate into the skin tissue. Compared with the comparative example 2 for the treatment of skin herpes induced by HSV-1F strain and Blue strain, it has a better therapeutic effect on F strain, but has no obvious therapeutic effect on Blue strain. Examples 3 and 4 significantly inhibited the formation of blisters around the lips and skin of HSV-1F strain and Blue strain mice in a dose-dependent manner.
[0086] Histopathological analysis of mouse lip and skin tissues was performed. Fig. 9 As shown, the skin tissue of the normal group of mice was observed under a microscope, and a dense and thin epidermis layer was first seen. The dermis is connected to the epidermis below, where collagen and elastic fibers form a reticular structure. The subcutaneous tissue is composed of loose connective tissue and fat. Most of the epithelial cells in the lips and skin of the mice in the virus control group and Example 2 group were lost or degenerated, and replaced by fibrin, inflammatory cells and cell fragments. The epidermis was ruptured, thickened, and had a hardened layer caused by scabs. At the same time, both the epidermis and dermis showed severe inflammatory cell infiltration, and the boundaries of each part became blurred. After treatment with traditional Chinese medicine monomer hydrogel, no obvious damage was found in the epidermis and dermis of the mouse skin, regardless of whether it was an infection induced by HSV-1F strain or Blue strain, which was similar to the healing of normal skin.
[0087] At the same time, the expression level of HSV-1 antigen in mouse skin tissue was detected to measure the viral replication, e.g. Fig.10As shown, the virus-mediated lesion area forms specific staining under immunohistochemical staining, and Examples 3 and 4 inhibit the replication of F strain and Blue strain in the tissue, that is, they show lighter staining or no staining. In contrast, Comparative Example 2 can only improve the skin herpes induced by HSV-1F strain, and has no protective effect on Blue strain, while Comparative Example 1 cannot provide protective effect under any circumstances.
[0088] As a functional hydrogel that responds to ROS, the level of ROS in the tissue was detected by cryosectioning. Fig.11 As shown, viral infection mediates a large amount of ROS accumulation, which presents red fluorescence after being bound by the probe. Example 2 provides a weak effect of phagocytizing ROS, and as the amount of baicalin loaded in Example 3 and Example 4 increases, their ability to clear ROS increases.
[0089] HSV-1 replicates in large quantities through lytic infection and activates the NF-κB pathway. Luo et al.'s previous study found that baicalin can inactivate HSV-1 and inhibit the phosphorylation of IKK and NF-κB. Therefore, the expression level of viral protein ICP27 in mouse tissues and the degree of activation of the NF-κB pathway after the treatment of skin herpes in the example were further analyzed by immunoblotting. Fig.12 and 13 As shown, ICP27 amplifies in large quantities after viral infection, and simply applying baicalin to the lesion cannot effectively relieve the symptoms of viral infection, which may be related to the easy oxidation of baicalin. Based on the material properties and functions of Example 2, baicalin is effectively wrapped in the hydrogel, isolating the external aerobic environment and promoting its tissue permeability. Therefore, after treatment with Examples 3 and 4, the virus level in the mouse tissue was reduced, and the NF-κB pathway was effectively inhibited.
[0090] Figure 7 The results of the efficacy of the examples and comparative examples in treating HSV-1 infection at the cellular level are as follows: Figure 7 (A) is the viral load of Examples 2, 3, 4 and Comparative Examples 1 and 2 in treating HSV-1F strain infection on Hacat and HFF-1 cells, Figure 7 (B) shows the viral load of HSV-1 acyclovir-resistant strains infected with Hacat and HFF-1 cells treated with Examples 2, 3, 4 and Comparative Examples 1 and 2, wherein green represents viral protein and blue represents cell nuclei.
[0091] Figure 8 The results of the examples and comparative examples on the animal level for treating HSV-1 infection-induced mouse skin herpes are shown in Table 1. Figure 8 (A) is a representative picture of the treatment of HSV-1F strain-induced mouse skin herpes in Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively. Figure 8(B) are representative pictures of the treatment of mouse skin herpes induced by acyclovir-resistant strain of HSV-1 by Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively.
[0092] Fig. 9 The H&E staining results of the examples and comparative examples for treating HSV-1 infection-induced mouse skin herpes at the animal level are as follows: Fig. 9 (A) is an H&E staining picture of the treatment of HSV-1F strain-induced mouse skin herpes in Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively. Fig. 9 (B) is an H&E staining picture of mouse skin herpes induced by HSV-1 acyclovir-resistant strain treated by Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively.
[0093] Fig.10 The following are the results of immunohistochemical staining of skin herpes in mice induced by HSV-1 infection in the examples and comparative examples at the animal level. Fig.10 (A) is the immunohistochemical staining of the skin herpes of mice induced by HSV-1F strain in Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively. Fig.10 (B) is the immunohistochemical staining of mouse skin herpes induced by HSV-1 acyclovir-resistant strains treated by Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively.
[0094] Fig.11 The results of the examples and comparative examples on reducing the ROS content in tissues when treating HSV-1 infected mouse skin herpes at the animal level are as follows: Fig.11 (A) is a representative picture of ROS detected in the tissue after treating HSV-1F strain-induced skin herpes in mice in Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively. Fig.11 (B) is a representative picture of ROS detected in the tissue after treating HSV-1 acyclovir-resistant strain-induced mouse skin herpes in Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively.
[0095] Fig.12 The results of the test on the viral protein ICP27 content in the treatment of HSV-1 infected mouse skin herpes at the animal level in the examples and comparative examples are as follows: Fig.12 (A) is the test results of viral protein ICP27 content in treating HSV-1F strain-induced mouse skin herpes in Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively. Fig.12 (B) is the detection result of viral protein ICP27 content in treating mouse skin herpes induced by acyclovir-resistant strain of HSV-1 in Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively.
[0096] Fig.13 The results of the test on the expression level of NF-κB pathway proteins in the treatment of skin herpes in mice infected with HSV-1 at the animal level in the examples and comparative examples are as follows: Fig.13 (A) is the expression level of NF-κB pathway proteins in treating HSV-1F strain-induced mouse skin herpes in Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively. Fig.13 (B) shows the expression levels of NF-κB pathway proteins in the treatment of HSV-1 acyclovir-resistant strain-induced mouse skin herpes in Examples 2, 3, 4 and Comparative Examples 1 and 3, respectively.
[0097] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A method for preparing a traditional Chinese medicine monomer hydrogel for treating herpes simplex type I, characterized in that: Chitosan reacts with p-formylphenylboronic acid and 3,4-dihydroxybenzaldehyde to undergo Schiff base reaction, and is then reduced and aminated under the action of sodium cyanoborohydride to obtain chitosan functionalized with phenylboronic acid and catechol, which is then mixed with a polyvinyl alcohol solution containing baicalein to obtain a Chinese medicine monomer hydrogel.
2. The method for preparing the Chinese medicine monomer hydrogel for treating herpes simplex type I according to claim 1, characterized in that: The chitosan has a medium viscosity, that is, a viscosity of 200-400 mPa·s.
3. The method for preparing the Chinese medicine monomer hydrogel for treating herpes simplex type I according to claim 1, characterized in that: The chitosan structure functionalized with phenylboronic acid and catechol is: Among them, m:n=1:1~10:
1.
4. The method for preparing the Chinese medicine monomer hydrogel for treating herpes simplex type I according to claim 1, characterized in that: The steps include: (1) dispersing baicalein in a polyvinyl alcohol solution to obtain a baicalein-polyvinyl alcohol mixed solution; (2) dissolving chitosan under acidic conditions, adding p-formylphenylboric acid, 3,4-dihydroxybenzaldehyde and sodium cyanoborohydride to react, dialysis and freeze-drying after the reaction, and re-dissolving to obtain a chitosan mixed solution; (3) Mix the baicalein polyvinyl alcohol solution and chitosan solution and vortex them in a mixer to prepare a mixed solution.
5. The method for preparing the Chinese medicine monomer hydrogel for treating herpes simplex type I according to claim 1, characterized in that: In the step (1), in the baicalein-polyvinyl alcohol mixed solution, the concentration of baicalein is 10.0 mM to 40.0 mM, and the concentration of polyvinyl alcohol is 1.0 wt% to 3.0 wt%.
6. The method for preparing the Chinese medicine monomer hydrogel for treating herpes simplex type I according to claim 1, characterized in that: The acidic condition in step (2) is glacial acetic acid with a concentration of 0.5wt% to 2.0wt%.
7. The method for preparing the Chinese medicine monomer hydrogel for treating herpes simplex type I according to claim 1, characterized in that: In the step (2), the p-formylphenylboronic acid and 3,4-dihydroxybenzaldehyde are dissolved in N,N-dimethylformamide respectively and then added.
8. The method for preparing the Chinese medicine monomer hydrogel for treating herpes simplex type I according to claim 1, characterized in that: In the step (2), after adding formylphenylboronic acid and reacting for 10h to 14h, 3,4-dihydroxybenzaldehyde is added and reacted for 10h to 14h, and sodium cyanoborohydride is added; the dialysis condition is a 14000 molecular weight dialysis bag, dialysis for 3 days, and water is changed three times a day; the freeze-drying time is 48h to 72h; in the reconstituted chitosan solution, the chitosan concentration is 1.0wt% to 2.0wt%; In the step (3), the baicalein polyvinyl alcohol solution and the chitosan mixed solution are mixed at a volume ratio of 1:0.5 to 1:1.3; and the vortex time is 0.5 min to 3.0 min.
9. A Chinese medicine monomer hydrogel for treating herpes simplex type I obtained by the preparation method of the Chinese medicine monomer hydrogel for treating herpes simplex type I according to any one of claims 1 to 8.
10. Use of the traditional Chinese medicine monomer hydrogel according to claim 9 as a drug for treating herpes simplex type I.
